By using our website you accept our cookies policy.Find out more

Biomedical Catalyst 2018 round 2: primer award

Registration is closed
Funding details
Registration opens
06 Aug 2018, 00:00
Registration closes
03 Oct 2018, 12:00
03 Oct 2018, 12:00
up to £5 million
Innovate UK

Biomedical Catalyst supports the development of innovative healthcare products, technologies and processes. These can include:

  • disease prevention and proactive management of health and chronic conditions
  • earlier and better detection and diagnosis of disease, leading to better patient outcomes
  • tailored treatments that either change the underlying disease or offer potential cures

This is a competition for a primer award in the Biomedical Catalyst.

The primer award supports a technical evaluation of your idea through to proof of concept in a model system, and can include:

  • experimental evaluation (at laboratory scale)
  • initial demonstration using in vitro and in vivo models (but not human clinical trials such as safety or efficacy)
  • exploring potential production mechanisms
  • early-stage prototyping
  • product development planning
  • intellectual property protection

The Biomedical Catalyst has 4 types of funding award. These are: feasibility, primer, early stage and late stage. The late stage award is running alongside this one. They are designed to help SMEs developing a product or process to provide an innovative solution to a health and care challenge. The scheme supports progression from initial concept through to late stage development.

Related Funding Opportunities

Horizon 2020: EIC Horizon Prize for 'Innovative Batteries for eVehicles (H2020-Batteries-EICPrize-2018)

Businesses can apply for a share of €10m to develop a safe and sustainable battery for electric-vehicles through the development of new materials.

Related Content

Biomedical Catalyst 2018 round 2: late stage
Apply for a share of up to £10 million to work on solving healthcare challenges in a clinical setting or a relevant late stage environment.
SBRI: antimicrobial resistance (AMR) in humans
Organisations can apply to develop innovations that address the challenges of antimicrobial resistance (AMR) in humans.
Diagnostic Evidence Workshops Announced
The NIHR Community Healthcare Medtech and In vitro Diagnostics Cooperative has organised a series of three workshops on Diagnostic Evidence.